HOME >> MEDICINE >> NEWS
European commission grants "orphan" status for new acute myeloid leukaemia treatment

Wyeth-Ayerst Pharmaceuticals, the pharmaceutical division of American Home Products Corporation (NYSE:AHP),announced today that the European Commission has designated Mylotarg(gemtuzumab ozogamicin)as an "orphan medicinal product." The Commission decision follows a positive opinion adopted on 13 September 2000 by the Committee on Orphan Medicinal Products (COMP) of the European Agency for the Evaluation of Medicinal Products (EMEA).

"We anticipate that Mylotarg will become an important treatment option for European patients aged 60 and over with CD33-positive relapsed acute myeloid leukaemia (AML)," says L. Patrick Gage, Ph.D., President, Wyeth-Ayerst Research. "Its mechanism of action focuses on using antibody-antigen specificity to target delivery of potent chemotherapy to myeloid leukaemic cells. This compound represents the first product from Wyeth's promising oncology pipeline."

As a designated orphan medicinal product, Mylotarg will have access to the Commission's "centralised" procedure for assessment of the marketing authorisation application. Orphan medicinal products are intended to treat patients with rare life-threatening or very serious diseases for which no satisfactory method of treatment exists or where the product will be of significant benefit.

Orphan medicinal products do not automatically qualify for approval under "exceptional circumstances," but companies that sponsor orphan products receive incentives for bringing these products to the market and to the patient. Such incentives include the possibility of protocol assistance from the EMEA and fee reductions for all types of centralised marketing authorisation evaluation activities. If approved by the EMEA, Mylotarg would be the first product available in Europe from a new class of anticancer therapy known as "antibody-targeted chemotherapy." Mylotarg utilizes a patented linker technology with a novel potent anti-tumor antibiotic, calicheamicin.

Mylotarg is being develo
'"/>

Contact: Roseann Ward
roseann.ward@ketchumcomms.co.uk
44-0-207-465-8752
Ketchum
14-Nov-2000


Page: 1 2 3

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. The European Society of Cardiology launches Women at Heart
3. Use of potentially inappropriate medications among elderly common in some European countries
4. European folic acid policies are not effective enough
5. New European cancer figures for 2004 major efforts needed against the big four killers
6. Third of European cancer patients use complementary and alternative therapies
7. A new service from the European Patent Office
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. European nations urged to ratify international treaty on tobacco control
10. Increased investment in radiotherapy will improve cure rates for European cancer patients
11. ESA looking for more European women to volunteer for WISE bed-rest study in Toulouse next year

Post Your Comments:
(Date:10/31/2014)... Missouri (PRWEB) October 31, 2014 With ... school, one Midwest optometrist feels they may overlook one ... to affect areas like concentration, school performance and even ... be too brief to identify progressive vision problems, and ... Joseph, Mo., announces a new initiative: The Awesome Eyes ...
(Date:10/31/2014)... News) -- Sleep apnea may make it hard for you ... car or left your house keys, a small study suggests. ... that this ability -- called spatial memory -- was impaired ... when other stages of sleep weren,t affected. REM sleep is ... "We,ve shown for the first time that sleep apnea, ...
(Date:10/31/2014)... that either they or a family member have experienced ... issue of The Gerontological Society of America,s Public ... goes on to show that Americans strongly support holding ... health care wishes. , This PP&AR , titled ... 12 articles that present new ways of understanding the ...
(Date:10/31/2014)... North Shore Eye Care today announced ... Island and the addition of leading ophthalmologist, William S. ... North Shore Eye Care Medical Director, Jeffrey Martin, MD. ... the Department of Ophthalmology of Winthrop-University Hospital and has ... for more than 30 years. He has been named ...
(Date:10/31/2014)... 31, 2014 FindSurrogateMother.com conveys ... gifts of life — building a family through surrogacy. ... mothers and donors with hopeful intended parents in turn ... , It’s a collective aptitude of surrogate mothers, intended ... and fertility clinics that help provide these connections — ...
Breaking Medicine News(10 mins):Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 2Health News:New School Vision Initiative Announced by Dr. Rosenak’s Optical Options; Program Aims to Help Recognize Unseen Vision Problems That Impact School Success 3Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Advance directives can benefit patients, families, and health care system 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3
(Date:10/31/2014)... 3, 2014 British Journal ... BPH to discuss "male orgasmic dysfunction" with their doctor ... treat prostate symptoms while preserving sexual function   ... publication of a paper in the British Journal of ... prostate to discuss with their doctors the likely impact ...
(Date:10/31/2014)... BARCELONA , October 31, 2014 ... two Australian patents of B. Braun Melsungen AG (B. Braun) ... safety IV catheters manufactured by Poly Medicure Ltd ... Australia proceeding number VID 463 of 2013 ... In the detailed judgment, Multigate was found to have infringed ...
(Date:10/31/2014)... 30, 2014 Migranade, Inc. announced today the ... to the 36 million U.S. migraine sufferers November, 2014. ... targets the actual cause of migraines and not just ... not the source Migranade is assured to be a ... Relief is available at http://www.migranade.com and will ...
Breaking Medicine Technology:Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2Game Changing Migraine Medication To Be Available November 2014 2
Cached News: